Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resistant Starch in Patients on Dual ICI
NCT04552418Phase 1Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Adherence to resistant starch supplement schedule at 13 weeks, Frequency of serious adverse events attributable to ICI therapy at 6 months and 1 more. Started Jun 2021; status: completed.
Beyond the preview
Go deeper on NCT04552418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552418.